5-Amino-1MQ

5-Amino-1MQ, short for 5-amino-1-methylquinolinium, is a small synthetic molecule, a methylquinolinium salt, rather than a true peptide, even though it is usually marketed and sold alongside peptides. It was designed by researchers as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that drew attention in the mid-2010s when its overactivity in fat tissue was tied to obesity and metabolic disease. Much of that foundational biology came from studies that silenced NNMT genetically, and the compound itself was introduced by Neelakantan and colleagues in a 2018 Biochemical Pharmacology paper describing membrane-permeable methylquinolinium NNMT inhibitors. In their diet-induced obese mice, the lead compound reduced body weight and fat mass without changing how much the animals ate. Because it targets an enzyme that is a normal part of physiology rather than a foreign invader, its story is closely tied to NAD+ and methylation biology. It has no natural role in the body of its own; it is an engineered tool compound that later migrated into the gray-market research-chemical space.

The main reason people look into 5-Amino-1MQ is fat loss and body recomposition, since animal work showed reduced fat mass driven by higher energy expenditure rather than appetite suppression. Related interest centers on metabolic health more broadly, including improved insulin sensitivity, better glucose handling, and support for the NAD+ pool that tends to decline with age and metabolic stress. A secondary theme is skeletal muscle, where NNMT inhibition has been explored for its potential to support muscle stem-cell activity and regeneration. Some users also chase day-to-day energy, endurance, and mental clarity, which are framed as downstream effects of restoring cellular NAD+. It is sometimes discussed in longevity stacks next to NAD+ precursors such as NMN or NR, though it works from the opposite direction by reducing waste rather than adding building blocks. One nuance worth keeping in mind is that the mechanism points toward people with metabolic dysfunction tied to excess body fat, not lean individuals hunting for a marginal edge.

NNMT normally takes nicotinamide, a form of vitamin B3, and methylates it into 1-methylnicotinamide, a product that then gets cleared from the body. That reaction pulls nicotinamide out of the salvage pathway, which is the main route cells use to regenerate NAD+, and it also consumes a methyl group from S-adenosylmethionine (SAM). This matters most in fat tissue, where the salvage pathway is the dominant source of NAD+ and NNMT is the primary enzyme clearing nicotinamide, so when NNMT is overexpressed it drains NAD+ and feeds a self-reinforcing cycle of impaired fat burning. 5-Amino-1MQ is a competitive and relatively selective inhibitor that slots into the NNMT active site and blocks it, which raises intracellular NAD+ and SAM. The distinctive part is what the extra SAM appears to do: it pushes the polyamine pathway to burn through acetyl-CoA, a raw material for making fat, which tilts cells away from fat storage and toward energy expenditure. In other words it is not an NAD+ booster in the usual sense; it works by plugging a leak rather than adding fuel.

5-Amino-1MQ is unusual among gray-market compounds in that it is taken almost entirely by mouth, typically as capsules, which suits a small molecule that can survive oral absorption. Rodent pharmacology suggests oral bioavailability around 38 percent and a half-life near 7 hours, which is part of why self-reported regimens describe splitting a daily amount into two or three doses across the day. Worth noting, the original mouse studies actually delivered the compound by subcutaneous injection, so the oral route that dominates human use is an extrapolation rather than the way the effect was first demonstrated. Its action is systemic rather than local, since it circulates and acts on tissues such as fat, liver, and muscle where NNMT is expressed. Some users report taking it earlier in the day to avoid sleep disruption, given its energizing profile. None of this constitutes a protocol; reported regimens are anecdotal and untested in controlled human trials.

The evidence base for 5-Amino-1MQ is almost entirely preclinical. The headline results come from mice, where diet-induced obese animals lost meaningful body weight and fat mass, with reported figures such as roughly a third reduction in fat-related measures and smaller fat cells, all without the animals eating less. Supporting data come from cell culture showing lower 1-methylnicotinamide and higher NAD+ and SAM after NNMT inhibition. There are no completed human clinical trials, no FDA-approved NNMT inhibitors, and no formal human safety data, so claims about fat loss, muscle, cognition, and longevity in people remain unproven extrapolations. It is also worth flagging that the striking animal results occurred in animals that already had elevated NNMT from obesity, meaning the compound corrected an existing dysfunction rather than enhancing a healthy baseline. Some clinicians report anecdotal patient experience, but that is not a substitute for controlled human research.

5-Amino-1MQ is not an approved drug anywhere; it has not been through FDA review and there are no approved NNMT inhibitors on the market. It is sold as a research chemical and is sometimes offered through wellness and anti-aging clinics, which places it in a legal gray area rather than a clear regulatory category. Because it is a small molecule and not a true peptide, it does not fit neatly into peptide-specific compounding rules, and product quality depends heavily on the vendor since there is no regulated supply chain. It is commonly listed under aliases such as 5-amino-1-methylquinolinium, 5-A1MQ, or simply five amino. It is not a scheduled controlled substance, but its unapproved status means the legality of sale and possession can vary and can change quickly. Anyone encountering it should treat marketing claims cautiously and remember that regulatory attention to novel metabolic compounds can shift fast.